DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 1

Completed

Conditions: Pancreatic Neuroendocrine Tumor

Interventions: Drug: RAD001
Drug: Temozolomide

First Posted Date: 2007-12-19

Last Posted Date: 2020-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT00576680

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Simvastatin in Waldenstrom's Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Simvastatin

First Posted Date: 2007-12-18

Last Posted Date: 2015-12-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00575965

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Adenosquamous Cell Carcinoma
Basaloid Squamous Cell Carcinoma
Undifferentiated Carcinoma

Interventions: Drug: Abraxane
Drug: Erbitux
Drug: Carboplatin
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2007-12-11

Last Posted Date: 2017-11-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00570674

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Graft-vs-Host Disease

Interventions: Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: Bortezomib

First Posted Date: 2007-10-24

Last Posted Date: 2014-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00548717

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Active After Cancer Trial (AACT)

Not Applicable

Active, not recruiting

Conditions: Breast Cancer
Colorectal Cancer

Interventions: Behavioral: Telephone-Based exercise intervention

First Posted Date: 2007-10-23

Last Posted Date: 2025-03-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 120

Registration Number: NCT00548236

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Phase 2

Completed

Conditions: Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Vaginal Cancer
Carcinoma of the Vulva

Interventions: Drug: Avastin

First Posted Date: 2007-10-17

Last Posted Date: 2017-03-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00545792

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2007-10-12

Last Posted Date: 2016-05-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00543114

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Carcinoma of the Breast

Interventions: Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2007-10-11

Last Posted Date: 2024-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 406

Registration Number: NCT00542451

Locations: 🇺🇸
Case Western University, Cleveland, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 17 locations

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Phase 1

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Interleukin-2

First Posted Date: 2007-09-14

Last Posted Date: 2020-07-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00529035

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function

Completed

Conditions: Ovarian Cancer

First Posted Date: 2007-09-05

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00525460

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy